These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 16680108)

  • 1. When the price is right.
    Nat Biotechnol; 2006 May; 24(5):473. PubMed ID: 16680108
    [No Abstract]   [Full Text] [Related]  

  • 2. A cancer drug shows promise, at a price that many can't pay.
    Berenson A
    N Y Times Web; 2006 Feb; ():A1, C2. PubMed ID: 16506302
    [No Abstract]   [Full Text] [Related]  

  • 3. PHARMAC responds on Herceptin assumptions and decisions.
    Metcalfe S; Evans J
    N Z Med J; 2007 Aug; 120(1260):U2692. PubMed ID: 17726504
    [No Abstract]   [Full Text] [Related]  

  • 4. Genentech relaunched with independence intact.
    Glaser V
    Nat Biotechnol; 1999 Jul; 17(7):634. PubMed ID: 10409348
    [No Abstract]   [Full Text] [Related]  

  • 5. PHARMAC's funding of 9 weeks Herceptin: many assumptions in a high-risk decision.
    Isaacs RJ; Frampton CM; Kuper-Hommel MJ
    N Z Med J; 2007 Aug; 120(1259):U2676. PubMed ID: 17721579
    [No Abstract]   [Full Text] [Related]  

  • 6. Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab?
    Hillner BE; Smith TJ
    J Clin Oncol; 2007 Feb; 25(6):611-3. PubMed ID: 17308264
    [No Abstract]   [Full Text] [Related]  

  • 7. Roche responds to the 'Herceptin or deception' article.
    Petersen S
    N Z Med J; 2006 Jul; 119(1237):U2069; author reply U2069. PubMed ID: 16862210
    [No Abstract]   [Full Text] [Related]  

  • 8. Why these biotechs are as hot as net stocks. Wall Street's betting big on a genetic technology that burned it badly before. Monoclonal antibodies still don't cure cancer--but this time they may actually pay off.
    McLean B
    Fortune; 2000 Jan; 141(1):132-4, 135. PubMed ID: 10788044
    [No Abstract]   [Full Text] [Related]  

  • 9. GlaxoSmithKline cancer drug threatens Herceptin market.
    Waltz E
    Nat Biotechnol; 2005 Dec; 23(12):1453-4. PubMed ID: 16333273
    [No Abstract]   [Full Text] [Related]  

  • 10. The art of mismanagement.
    Nat Biotechnol; 2006 Nov; 24(11):1300. PubMed ID: 17093455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health economics in the Journal of Clinical Oncology and an evaluation of the indirect costs and benefits associated with adjuvant trastuzumab.
    de Lima Lopes G; Gluck S
    J Clin Oncol; 2007 Aug; 25(22):3382-3; author reply 3383. PubMed ID: 17664490
    [No Abstract]   [Full Text] [Related]  

  • 12. [Pharmaceuticals can be cost-effective in the long run].
    Jönsson B; Wilking N
    Lakartidningen; 2010 Apr 21-27; 107(16):1081-5. PubMed ID: 20476706
    [No Abstract]   [Full Text] [Related]  

  • 13. The ranibizumab saga of drug profiteering.
    Lee AC; Radford J
    BMJ; 2008 Sep; 337():a1532. PubMed ID: 18768564
    [No Abstract]   [Full Text] [Related]  

  • 14. Battle over eye medicine gives drugmaker a dose of reality.
    Hayden EC
    Nat Med; 2008 Feb; 14(2):108. PubMed ID: 18256604
    [No Abstract]   [Full Text] [Related]  

  • 15. [High cost of trastuzumab for the treatment of mammary carcinoma in The Netherlands].
    Offerhaus L
    Ned Tijdschr Geneeskd; 2006 Jun; 150(25):1426-7; author reply 1427. PubMed ID: 16841595
    [No Abstract]   [Full Text] [Related]  

  • 16. The socialite scientist.
    Serwer A
    Fortune; 2002 Apr; 145(8):152-4, 158, 160 passim. PubMed ID: 11961885
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
    Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
    Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects and costs of adjuvant chemotherapy for operable lymph node positive breast cancer with HER2/neu overexpression].
    Bult P; Tjan-Heijnen VC; van Krieken H
    Ned Tijdschr Geneeskd; 2006 Jul; 150(26):1481; author reply 1481-3. PubMed ID: 16875274
    [No Abstract]   [Full Text] [Related]  

  • 19. Growing pains for biopharmaceuticals.
    Ashton G
    Nat Biotechnol; 2001 Apr; 19(4):307-11. PubMed ID: 11283578
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of trastuzumab for metastatic breast cancer in Australia: inaccurate results and alternative interpretation of findings.
    Chan A; de Boer R
    J Clin Oncol; 2007 Dec; 25(35):5662-3; author reply 5663-4. PubMed ID: 18065740
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.